Acquisition Announced
Lilly acquisition of Vaccine Company
US$1.6bn consideration
Announced 26 May 2026
Advisers
Vaccine Company
Target
- Financial adviser
- Legal adviser
Lilly
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- Vaccine Company
- Acquirer
- Lilly
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Eli Lilly acquisition of Curevo Vaccine May 2026 · US$1.5bn · Biotech
- Gilead acquisition of Ouro Medicines Mar 2026 · US$1.7bn · Biotech
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
Sources
- 26 May 2026 Vaccine Company to be Acquired by Eli Lilly for up to $1.5 Billion cooley.com
- 26 May 2026 Press release (PR Newswire), Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases prnewswire.com
- 8 Jul 2026 Lazard: UNITED STATES Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases lazard.com
